



Andrew C. Leon Distinguished Career Award

Stephen R. Marder, MD





Phil May



Wayne Fenton




Ted Van Putten



Ellen Stover



Jerry Hogarty



Thoughts on
treatment
development
for CNS
disorders

Why are we moving slower
than other therapeutic areas?

Lessons over the years

Advancing treatment
discovery

Why such slow progress

- **Complexity of psychiatric disorders**
- **Unrealistic expectations about what a drug or other somatic treatment can do**
- **Interventions are often too late to affect disease progression**

Subjective Response to Antipsychotic Drugs

Theodore Van Putten, MD; Philip R. A. May, MD; Stephen R. Marder, MD; Lorraine A. Wittmann

(Arch Gen Psychiatry 38:187-190, 1981)

Response to Antipsychotic Medication: The Doctor's and the Consumer's View

Theodore Van Putten, M.D., Philip R.A. May, M.D., and Stephen R. Marder, M.D.

(Am J Psychiatry 141:16–19, 1984)

Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes

(Am J Psychiatry 2003; 160:1405–1412)

Stephen R. Marder, M.D.
Shirley M. Glynn, Ph.D.
William C. Wirshing, M.D.
Donna A. Wirshing, M.D.
Doreen Ross
Clifford Widmark, M.D.
Jim Mintz, Ph.D.
Robert P. Liberman, M.D.
Karen E. Blair, M.S.

- **Our endpoint measures may not reflect what our patients value**

Supplementing Clinic-Based Skills Training With Manual-Based Community Support Sessions: Effects on Social Adjustment of Patients With Schizophrenia

(Am J Psychiatry 2002; 159:829-837)

Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia

Michael C Davis^{1,2}, Michael F Green^{1,2}, Junghee Lee^{1,2}, William P Horan^{1,2}, Damla Senturk³, Angelika D Clarke^{1,2} and Stephen R Marder^{*1,2}

Neuropsychopharmacology (2014) 39, 2070-2077

Shirley M. Glynn, Ph.D.

Stephen R. Marder, M.D.

Robert P. Liberman, M.D.

Karen Blair, M.S.

William C. Wirshing, M.D.

Donna A. Wirshing, M.D.

Doreen Ross

Jim Mintz, Ph.D.

It is unrealistic to expect a drug or a somatic treatment to affect long-standing mental processes and behaviors.

Final thoughts

- **Our clinical endpoints should be re-evaluated**
- **Subjective experiences from somatic interventions should be considered**
- **We should use our drugs and other somatic treatments to facilitate learning**
- **Interventions should be implemented as early in disease processes as possible**